Legal Opinion
In re Lipitor Antitrust Litigation
District Court, D. New Jersey
Decided September 12, 2014No. Civil Action No. 3:12-cv-02389 (PGS)PublishedCited by 10 opinions
1Opinion of the Court
MEMORANDUM
PETER G. SHERIDAN, District Judge.
This matter comes before the Court on two motions to dismiss the Amended Complaint for failure to state a claim. Fed.R.Civ.P. 12(b)(6). It is an antitrust action which concerns the legality of a settlement between two drug manufacturers, Pfizer and Ranbaxy, regarding the pharmaceutical drug atorvastatin calcium under the brand name Lipitor® (“Lipitor”). Plaintiffs are direct purchasers of Lipitor seeking recovery of overcharges that were allegedly caused by the delayed entry provision of the settlement. In their amended complaint (ECF No. 472),…
2Cases cited38 opinions
- Ashcroft v. IqbalSupreme Court of the United States · 2009
- Bell Atlantic Corp. v. TwomblySupreme Court of the United States · 2007
- Phillips v. County of AlleghenyCourt of Appeals for the Third Circuit · 2008
- Pension Benefit Guaranty Corporation v. White Consolidated Industries, Inc., C/o Ct Corporation Systems Registered AgentCourt of Appeals for the Third Circuit · 1993
- Dura Pharmaceuticals, Inc. v. BroudoSupreme Court of the United States · 2005
33 more not listed; retrieve them via the Exa API.
3Cited by10 opinions
- In Re Lipitor Antitrust LitigationCourt of Appeals for the Third Circuit · 2017
- In Re Lipitor Antitrust LitigationCourt of Appeals for the Third Circuit · 2017
- In re Aggrenox Antitrust LitigationDistrict Court, D. Connecticut · 2015
- American Sales Co. v. Warner Chilcott Co.Court of Appeals for the First Circuit · 2016
- United Food & Commercial Workers Local 1776 v. Teikoku Pharma USA, Inc.District Court, N.D. California · 2014
5 more not listed; retrieve them via the Exa API.